CC chemokine receptors: latest news on Beta chemokine receptor therapeutics
Technical breakthrough · 30. June 2021
SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to modified peptides, DNA and cell immunization strategies
Chemokine receptors: a promising GPCR family to target?
Technical breakthrough · 10. June 2021
SYnAbs develops anti-chemokine receptors monoclonal antibodies with therapeutic effect for Biotech and Pharma companies

Functional antibodies: B-cell depleting antibodies
Technical breakthrough · 09. April 2021
To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.
SYnAbs and Belgian Volition ink strategic agreement on epigenetics
Technical breakthrough · 19. March 2021
SYnAbs enters in a strategic agreement with Volition to generate monoclonal antibodies against epigenetics biomarkers including modifications of histones and DNA, histone variants, and proteins associated with nucleosomes

Viral Envelope Proteins,  targets for Therapeutic Neutralizing Antibodies (NAbs)
Technical breakthrough · 08. March 2021
How to generate effective neutralizing antibodies to target infectious disease transmembrane protein antigens. A review of the technical challenges, strategies, and risks.
Anti-drug antibody generation :  How to effectively monitor your therapeutic drug
Technical breakthrough · 20. February 2021
SYnabs generate anti-drug antibodies for small molecules and therapeutic antibodies. Paratope-specific anti-idiotype antibodies, non-inhibitory anti-idiotype antibodies, or drug-target complex binders generation.

How do ion channels work?
Technical breakthrough · 25. January 2021
SYnAbs develops therapeutic effector monoclonal antibodies against ion channel transmembrane proteins thanks to DNA and cell immunization technologies
A brief history of the discovery of ion channels
Technical breakthrough · 11. January 2021
From Galvani' spark to the three-dimensional structure of ion channels, learn the fabulous history of unique transmembrane proteins

Technical breakthrough · 14. December 2020
Molecular dynamics of G protein-coupled receptors (GPCRs) and unique monoclonal antibody effectors and binders targeting GPCR.
Technical breakthrough · 28. November 2020
SYnAbs unique anti-androstanolone (anti-DHT) monoclonal antibodies of a pg sensitivity level and no cross-reactivity to free testosterone

Show more